相关实验视频

Updated: Jan 15, 2026

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

纳灵宁:在肝细胞癌中调节血管生成和免疫反应的潜在治疗剂

Wenmei Wu¹, Xiangyu Qiu¹, Xiaofan Ye¹

¹Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.

Journal of pharmaceutical analysis

|October 13, 2025

概括

纳灵宁通过阻断血管形成和增强抗瘤免疫力来抑制肝癌的生长. 它针对VEGFA和c-Met蛋白质,为肝细胞癌 (HCC) 提供了潜在的新疗法.

科学领域:

生物化学生化学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

类生物类生物黄类的纳灵宁因其在代谢和心血管健康方面的作用而闻名.
它在抗血管生成和抗瘤免疫的具体机制,特别是在肝癌中,仍然不清楚.

研究的目的:

为了研究纳灵宁对肝细胞癌 (HCC) 的抗癌作用.
阐明纳林根因对血管生成和抗瘤免疫力的作用的分子机制.

主要方法:

使用HCC细胞系和动物模型进行体外和体外研究.
人的静脉内皮细胞 (HUVEC) 管形成和迁移试验.
肉胆 ?? 膜 (CAM) 测试用于新血管化.
对CD8+T细胞水平和免疫细胞因子的分析.
对VEGFA和c-Met.Met的K48相关的泛化和蛋白质降解途径的研究.

主要成果:

纳灵宁在体外和体内都显著抑制了HCC细胞的生长.
纳灵宁减少了内皮细胞管的形成,迁移和新血管化.
纳灵宁增加了瘤微环境中的CD8+T细胞水平和免疫细胞因子.
纳灵宁促进了K48相关的泛化和VEGFA和c-Met的降解,降低了PD-L1表达.
与纳灵宁和PD-L1抗体或贝瓦齐祖马布的联合治疗显示出增强的治疗效果.

结论:

纳灵宁在HCC中表现出强大的抗血管和抗瘤免疫特性.
该机制涉及K48相关的VEGFA和c-Met的泛化和降解.
纳灵宁代表了肝癌的有希望的治疗候选者,可能增强目前的免疫疗法.

关键词:

血管新生的产生.肝细胞癌是肝细胞癌.免疫抑制可以抑制免疫力.在Naringenin,我们可以看到.在PD-L1中.在VEGFA中,VEGFA是VEGFA.在c-Met Met中使用.

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Rat Mesentery Angiogenesis Assay

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...